


FutureBridge

Food & Nutrition

# GLP-1 Appetite Shift

How GLP-1 is reshaping food decisions and driving new nutritional norms in the industry.

Semaglutide



21%

estimated fewer calories  
consumed by the average GLP-  
1 user annually relative to  
before starting medication

Source: KPMG

# Contents


**1. Introduction:**  
Appetite, Innovation, Impact

**2. Market Shift:**  
Consumers, Drivers, Restraints

**3. Innovation Movers:**  
Players, Launches, Patents

**4. What Your Next Move?:**  
Key actions and FutureBridge support

# FutureBridge

A man in a red shirt is looking into an open refrigerator. Inside the refrigerator, there are several plastic water bottles in the foreground, a carton of milk, and some condiments on the shelf. The man is looking towards the left side of the refrigerator.

## 1. Introduction: Appetite, Innovation, Impact

---

GLP-1 medications are transforming how consumers eat, shop, and prioritize health. Appetite suppression is just the beginning; these medications are sparking widespread ripple effects across categories, spending, and brand innovation.

# The GLP-1 Appetite Revolution

---

**GLP-1 is changing how, what, and why people eat. Appetite suppression is real. Consumer behavior is shifting fast.**

**66mn**

expected GLP-1 users in the US by 2034

**31%**

of GLP-1 users spend less on groceries monthly

## KEY FINDINGS:

- Portion control, protein, and fiber are top priorities
- Sugar-heavy, indulgent, and impulse categories face decline
- Three personas emerge: trend-led, goal-driven, and practical
- Functional, convenient, trusted food formats gain share
- Healthcare providers are influencing choices more than ever
- Retailers watch basket sizes shrink, and trading patterns shift

## ACTION REQUIRED

1. Reformulate, resize, and reposition core products
2. Prioritize clear metabolic benefits, not just claims
3. Adapt fast to protect volume, margin, and brand relevance

**GLP-1 is not a trend. It's a structural demand shift.**

# What if...

---

**...traditional food categories vanish and are replaced by function-first formats?**

**...snack shelves shrink by 50%, and wellness aisles double in size?**

**...alcohol becomes a redundant category among health-first consumers?**

GLP-1 is not just a pharmaceutical story. It is a fundamental shift in how food is valued, marketed, and consumed. Appetite control is the gateway. The deeper disruption lies in how food brands must unlearn legacy assumptions and rebuild their innovation pipelines around health-first principles.

Brands that wait for reactive cues risk being outpaced by bold players already pivoting to precision nutrition, portioned indulgence, and science-backed claims. This is not a moment for optimization. It is a reset.

## 2. Market Shift: Consumers, Drivers, Impacts

---

This section explores the demographic makeup, behavioral shifts, key motivations, and emerging trends triggered by GLP-1 adoption.

# GLP-1: A Market Transformer

---

GLP-1 medications are creating ripple effects across the global food system. From consumer calorie intake to overall category performance, the data points to significant disruption.

**66mn**

expected GLP-1 users in the US by 2034

**31%**

of GLP-1 users spend less on groceries monthly

**2.5%**

drop in national calorie intake projected by 2035

**+29%**

CAGR expected in global GLP-1 market through 2030

# Rethinking Appetite Norms

---

**GLP-1 is shifting consumer priorities toward function over habit. Appetite suppression is now driving cleaner, smaller, and more intentional eating choices.**

## 1 Less in More

Appetite suppression among GLP-1 users leads to lower calorie intake and smaller portion sizes, driving growth in mini meals, single-serve packs, and snackable nutrition formats.

## 2 Health Before Habit

Consumers are now prioritizing metabolic and nutritional health over taste-driven routines, increasing demand for clean-label, high-protein, low-sugar, and functional food solutions.

## 3 Indulgence to Innovation

Traditional indulgent items like confectionery, snacks, and soft drinks are being swapped out for protein-rich snacks, drinks with adaptogens, and mood-boosting or hunger-regulating ingredients

# Forces shaping the shift

---

GLP-1 medications are accelerating change across the food sector while exposing vulnerabilities in product development and access. The following forces define where momentum will build and where friction may limit scale. Understanding this balance is key for strategic positioning.

## Key Drivers

### Calorie Awareness

Users are demanding low-calorie, high-nutrition alternatives

### Lifestyle Medicine

Behavior change is extending beyond prescription use

### Product Reformulation

Brands are racing to meet emerging preferences

### Demographic Growth

Affluent, younger users are driving early uptake

## Key Restraints

### Cost Barriers

Access remains limited by affordability

### Side Effects

Consumer hesitancy is still a risk

### Slow Regulation

Claim and labeling lag hinders reformulation

### Limited Global Reach

Uptake is concentrated in developed markets

# GLP-1: A Market Transformer

GLP-1 users are not a monolith. Their motivations, purchasing decisions, and dietary priorities vary widely. By understanding these personas, food and nutrition companies can better match product formats, marketing language, and innovation to emerging consumer segments. These examples represent key user mindsets shaping market demand.

	THE TREND TRACKER	THE CALORIE STRATEGIST	THE PRACTICAL PLANNER
<b>Age / Socio-Economic Group</b>	25–39 Affluent, urban, top 30% income bracket	35–55 Middle to upper-middle income	40–65 Value-conscious, modest income
<b>Family / Living</b>	Single or DINKs Urban renters, digitally native	Parents or couples Suburban, routine-led	Multigenerational or caregiver households Suburban/rural
<b>Supporting Data</b>	71% of GLP-1 weight loss users are GenX/Millennials	21% fewer calories consumed annually	49% are buying more affordable food
<b>Habits &amp; Motivations</b>	Trend-led, socially influenced, explores proactively	Goal-focused, structured, tracks intake	Seeks convenience, routine, low effort integration
<b>GLP-1 Mindset</b>	Early adopter, self-optimiser	Analytical optimizer, driven by results	Follows HCP guidance, focuses on outcomes
<b>What They Need</b>	Novel, branded formats: shots, smart snacks, protein	Portion-controlled meals, functional dairy, low-GI carbs	Affordable staples with metabolic benefits: fortified frozen meals, simple labels

# From Calories to Consciousness

---

GLP-1 users are exhibiting distinct shifts in how they consume, shop, and define food value. These changes offer both immediate category disruption and longer-term cues for innovation across health-forward platforms.



## 1. Reassess Impulse-Led Exposure

GLP-1 users consume fewer calories, reducing demand for non-essential items like candy, chips, and soda. Impulse-driven purchases are notably declining.



## 2. Prioritise Nutrient Density

Smaller appetites demand more from less. Reformulate around concentrated nutrition and functional efficiency.



## 3. Prepare for Alcohol Volume Reset

Alcohol consumption patterns are shifting. Scenario-plan for long-term category contraction and non-alc transitions.



## 4. Enable Compressed Nutrition

Fewer eating occasions require products that deliver complete macros. Focus innovation on convenient, balanced formats.




## 5. Expand Hydration Strategy

Hydration is becoming a functional anchor. Explore whitespace in cognitive, recovery, and performance territories.

# GLP-1 Users Reduce Processed First

Individuals using GLP-1 medications for weight loss demonstrate a notably greater reduction in their consumption of snacks, sugary drinks, baked goods, and confectionery compared to non-users – putting these categories at greater risk.

## GLP-1 Impact: % of respondents cutting back, by category



Note: Degree of cutback represents how much spending is being reduced by GLP-1 consumers

Source: [Morgan Stanley Research](#); [PWC](#);

According to a [recent study](#), semaglutide may influence taste pathways and brain regions related to taste processing, potentially reducing the desire for sweet and energy-dense foods in individuals with obesity. The study also reported an increased preference for whole foods, including fruits, vegetables, legumes, poultry, and fish. On average, GLP-1 users spend approximately 11% less across most food categories

## 3. Innovation Movers: Players, Launches, Patents

This section explores how leading brands and emerging players are reacting to GLP-1 disruptions through reformulated offerings, targeted claims, and strategic innovation pipelines.

# Key Players – Established Brands

As established players adapt to the GLP-1 era, their strategies reflect the scale and urgency of change. Appetite control, portion precision, and functionality are becoming central pillars in reformulation.

## Nutritional leaders adapting to the GLP-1 wave

COMPANY	FOCUS AREA	STRATEGIC ACTION
 CONAGRA BRANDS	Healthy Managed Meals Range	Launch of GLP-1 friendly nutrition meals
 NUTRA BALANCE	Therapeutic meal kits	Functional Kits for GLP-1 users
 Nestle	Health science, protein products	Protein drink messaging, mini-meals and meal kits
 Abbott	Medical nutrition & diagnostics	Convenient weight management solutions
 Herbalife	Weight management, protein drinks	Expanded portion-size offerings
 ADM	Functional ingredient innovation	Started a platform service for ingredients

# Conagra: Simple 'GLP-1 Friendly' Messages



Positioned for GLP-1 users through clear, front-of-pack nutritional signals, high protein, fiber, and GLP-1 friendly messaging.

## Conagra Brands



HQ: USA

Launch Date: 2024




**Health Claim:** Supports GLP-1-friendly diets

**Key Ingredients:** Chicken breast, edamame, broccoli, carrots, red peppers

**Product Type:** Frozen Ready Meals

# Nutrabalance: Reformulating Functional Kits for GLP-1 Users



A smart nutrition kit that balances protein, omega-3s, and adaptogens to support reduced appetite and energy needs.

## Nutrabalance



HQ: Australia

Launch Date: 2024

Health Claim: Balanced Nutrition for appetite support

Key Ingredients: Protein isolate, adaptogens, omega-3

Product Type: Single-serve nutritional kits

# Nestlé Health Science Expands to Metabolic Nutrition



Designed meals and drinks that cater to GLP-1 users' appetite control while delivering metabolic support.

Nestlé



HQ: Switzerland

Launch Date: 2023-24



Health Claim: Supports controlled hunger and energy

Key Ingredients: Whey protein, fiber, magnesium

Product Type: Meal portions and drinks

# Abbott: From Diagnostics to Portion Control Nutrition

---



A clinical-grade drink providing essential nutrition in compact servings for those with reduced food intake.

## Abbott



**Abbott**

HQ: United States

Launch Date: 2023



**Health Claim:** Complete nutrition for reduced intake

**Key Ingredients:** Protein blend, vitamins, fiber

**Product Type:** Ready-to-drink clinical nutrition

# Herbalife: Lifestyle Health Meets Portion Innovation



Protein-focused shakes tailored to deliver satiety with every scoop for health-conscious consumers managing reduced intake.

## Herbalife Nutrition

**Herbalife**



**HQ: United States**


**Launch Date: 2024**

**Health Claim:** Supports satiety and controlled calories

**Key Ingredients:** Plant protein, multivitamin complex

**Product Type:** Powder shakes with portion control

# ADM: Functional Ingredient Platform Targeting GLP-1 Effects



**ADM**



**HQ: United States**

**Launch Date: 2025**

**Health Claim:** Enhances satiety and metabolic health

**Key Ingredients:** Soluble fiber, chromium, adaptogens

**Product Type:** Ingredient platform for co-branding

# Emerging Innovators

Newer players are entering with personalized, science-driven propositions built to meet the emerging nutritional needs of GLP-1 users. These startups emphasize personalization, convenience, and functional efficiency.



HQ: China

Patent No: [CN118421537A](#)



**Key Technology:** Functional strain + powder formulation of microbial inoculum

**Health Claim:** Inhibits weight gain, lowers glucose, and increases GLP-1 via GPR120 activation

**Application:** Probiotic-based functional food



Beauty Health Nutrition

HQ: Japan

Patent No: [JP2024120867A](#)

**Key Technology:** Manuka leaf and bark extract processed via solvent extraction and drying

**Health Claim:** Supports GLP-1 release while regulating postprandial glucose and improving metabolic profiles

**Application:** Botanical-based functional food



HQ: Denmark

Patent No: [WO2024/141619 A1](#)

**Key Technology:** Pulsed energy drying of Brassica plant matter under 60°C

**Health Claim:** Supports GLP-1 release while regulating postprandial glucose and improving metabolic profiles

**Application:** Plant-based functional ingredient (powder, bar, gel)

## 4. What's Your Next Move in the GLP-1 Era?

GLP-1 is reshaping what, when, and why consumers eat. Now is the time for food companies to act with precision. Realign innovation, positioning, and portfolios to meet this profound behavioral shift.

# GLP-1 - Changing Food & Beverage Consumption Scenario

GLP-1 is driving permanent behaviour change. The Trend Tracker wants innovation and control. The Calorie Strategist seeks precision and planning. The Practical Planner prioritises simplicity and value. Appetite is down. Expectations are up. Action is essential. FutureBridge recommends four clear actions to convert disruption into competitive advantage:



## Appetite Reframe

*GLP-1 users feel less hunger but want purposeful nourishment when they do eat.*

We help identify white spaces for nutrient-dense, smaller-portion formats aligned to new eating cadences.



## Sugar Sensitivity

*Tolerance for sweetness is declining, forcing a rethink of indulgence and formulation.*

We map the sugar-reduction and sweetener innovation landscape to inform reformulation strategies.



## Protein Precision

*Satiety and muscle preservation are placing protein-rich innovation at the center.*

Our innovation radar tracks protein trends across regions, sources, and claim spaces to guide R&D.



## Brand Repositioning

*Brands must signal control, health, and simplicity while maintaining appeal.*

We co-create new brand narratives and sensory identities that align with evolving wellness expectations.

**GLP-1 is not a trend. It is a behavioral reset. The winners will be those who innovate with empathy and precision.**

# An appetite reset by 2030

---

Appetite suppression is not a trend. It is a reset. The global GLP-1 market is forecast to reach \$100 billion by 2030\*, reshaping how food is formulated, marketed, and consumed. This reset can be structured into four zones of ‘appetite’:

- 1. Prevent** – Proactive formulations that support metabolic health before pharmaceutical intervention is needed.
- 2. Portion** – Structurally designed formats that align with reduced appetite and promote calorie control.
- 3. Replace** – Smart reformulations that deliver indulgence with lower sugar, fewer calories, and better glycemic profiles.
- 4. Fortify** – Nutrient-enhanced products that replenish what suppressed appetite may reduce, from protein to micronutrients.

## Next Steps:


- Reformulate Portfolio** – Audit current products for portion fit, protein density, and sugar levels.
- Scout Partnerships** – Track and partner with emerging functional brands and platforms.
- Claims Strategy** – Align messaging with satiety, metabolic health, and mindful eating.

Between 2025 and 2030, we anticipate an accelerated shift from Prevent (healthier reformulation) to Portion (calorie and volume reduction) to Replace (total category substitution or bypass).

\*Source: Goldman Sachs Research

# The four zones of appetite...

Quick-win formats in Portion and Fortify zones offer scalable entry points, while Prevent and Replace unlock longer-term brand leadership. Leaders should activate near-term opportunities while incubating high-barrier, high-reward innovations in parallel.



# How FutureBridge Supports Your GLP-1 Strategy

FutureBridge enables food leaders to develop strategies to meet the four zones of appetite and act on the disruption created by GLP-1 across the value-chain.

Value Chain	Growth Play 2025-30	Capability Need
Upstream agri-inputs	Higher demand for specialty pulses, mycoprotein, precision-fermented dairy proteins; lower demand for HFCS & certain oils.	Contract farming, alternative-protein tech partnerships
Processing & manufacturing	Flexible small-batch lines, high-moisture extrusion, aseptic protein RTD fillers.	CapEx in multi-protein lines; rapid SKU change-over
Packaging	Shift from family to single-serve even as unit volumes rise but tonnage falls; F-pack label space needed for protein call-outs.	Lightweight rigid cups, recyclable mono-material flexibles
Distribution & retail	Store-within-store “GLP-1 wellness” bays, tele-nutrition bundle (drug + companion foods).	Joint ventures with pharmacy chains, AI-driven Planogram refresh
Brand & marketing	Science-backed nutrition authority, influencer-RDs, avoid explicit drug claims.	Evidence dossiers, healthcare-provider outreach, precision media

# Meet the experts

---

## Rima Mittra

---



### Associate Director: Food & Nutrition

Rima Mittra is a seasoned techno-commercial leader with over 15 years of experience in the food and nutrition industry. She specializes in translating emerging innovations and market trends into strategic, actionable insights. Renowned for her expertise in portfolio strategy planning, Rima combines deep technical knowledge with sharp commercial acumen to guide forward-looking decisions that shape competitive advantage.

## Edward Bergen

---



### Principal: Insights & Strategic Marketing

Edward Bergen is a Principal Analyst at FutureBridge, driving strategic insight across the food & nutrition and chemicals & materials practices. With over a decade of experience in the food industry, he delivers forward-looking perspectives on the future of food. Edward is known for his engaging speaking style and passion for storytelling.

**Plan Your GLP-1 Response**



# Our addresses

---



## North America

55 Madison Ave, Suite 400,  
Morristown, NJ 07960, USA



## Europe

WTC Utrecht, Stadsplateau 7,  
3521 AZ Utrecht, The Netherlands



## United Kingdom

Holborn Gate, 330 High Holborn  
London, WC1V 7QH, UK



## Asia Pacific

Millennium Business Park, Sector 3,  
Building # 4, Mahape, Navi Mumbai, India



FutureBridge is a techno-commercial consulting and advisory company. We track and advise on the future of industries from a 1-to-25-year perspective.



[www.futurebridge.com](http://www.futurebridge.com)